D. Scott Coward - 23 Mar 2026 Form 4 Insider Report for EXACT SCIENCES CORP (EXAS)

Reporting relationship: Director
Issuer ticker: EXAS
Reported as of: 23 Mar 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 23 Mar 2026, 09:19:46 UTC
Prior SEC filing: 16 Jun 2025
Source filing: View source filing
Reporting owner signature: /s/ D. Scott Coward by Mark Busch, attorney-in- fact

Key filing fact

D. Scott Coward filed Form 4 for EXACT SCIENCES CORP (EXAS) on 23 Mar 2026.

Key facts

This page summarizes D. Scott Coward's Form 4 filing for EXACT SCIENCES CORP (EXAS).
6 reported transactions and 3 derivative rows are listed below.
Accepted by SEC: 23 Mar 2026, 09:19.

Change

Previous filing in this sequence was filed on 16 Jun 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001247296 Primary reporting owner

COWARD D SCOTT

Relationship: Director
Address: C/O EXACT SCIENCES CORP., 5505 ENDEAVOR LANE, MADISON
Signature: /s/ D. Scott Coward by Mark Busch, attorney-in- fact
Signature date: 23 Mar 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

EXAS transaction

Common Stock

Disposed to Issuer

Transaction value
Shares: -52,164
Change %: -91%
Price
Shares after: 5,398
Date: 23 Mar 2026
Ownership: Direct
Footnotes: F1

EXAS transaction

Common Stock

Disposed to Issuer

Transaction value
Shares: -5,398
Change %: -100%
Price
Shares after: 0
Date: 23 Mar 2026
Ownership: Direct
Footnotes: F2

EXAS transaction

Common Stock

Disposed to Issuer

Transaction value
Shares: -4,694
Change %: -100%
Price
Shares after: 0
Date: 23 Mar 2026
Ownership: Held in 401(k) Plan
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

EXAS transaction Derivative

Stock Options (Right to Buy)

Disposed to Issuer

Transaction value
Shares: -4,175
Change %: -100%
Price
Shares after: 0
Date: 23 Mar 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 4,175
Exercise price: $44.37
Footnotes: F3, F4

EXAS transaction Derivative

Stock Options (Right to Buy)

Disposed to Issuer

Transaction value
Shares: -10,786
Change %: -100%
Price
Shares after: 0
Date: 23 Mar 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 10,786
Exercise price: $92.62
Footnotes: F4, F5

EXAS transaction Derivative

Stock Options (Right to Buy)

Disposed to Issuer

Transaction value
Shares: -12,875
Change %: -100%
Price
Shares after: 0
Date: 23 Mar 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 12,875
Exercise price: $98.18
Footnotes: F4, F6

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

D. Scott Coward is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 6 footnotes

Footnote F1

On March 23, 2026, pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of November 19, 2025, by and among Exact Sciences Corporation, a Delaware corporation (the "Issuer"), Abbott Laboratories, an Illinois corporation ("Parent"), and Badger Merger Sub I, Inc., a Delaware corporation and a direct, wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a direct, wholly owned subsidiary of Parent. At the effective time of the Merger (the "Effective Time"), on the terms and subject to the conditions set forth in the Merger Agreement, each share of the Issuer's common stock, par value $0.01 per share ("Common Stock"), issued and outstanding immediately prior to the Effective Time, with certain exceptions, was converted into the right to receive $105.00 in cash, without interest (the "Merger Consideration").

Footnote F2

At the Effective Time, each share of Common Stock subject to vesting, repurchase or other lapse restriction and that was granted under an Issuer stock plan and outstanding as of immediately prior to the Effective Time was deemed to be fully vested and cancelled and converted into the right to receive the Merger Consideration, less any applicable tax withholding.

Footnote F3

These options became exercisable on February 27, 2022.

Footnote F4

At the Effective Time, each option to purchase shares of Common Stock granted under an Issuer stock plan and outstanding and unexercised as of immediately prior to the Effective Time was cancelled and, in the case of any such option the per-share exercise price of which was less than the Merger Consideration, converted into the right to receive a cash payment equal to the number of shares of Common Stock for which such option was exercisable multiplied by the excess of the Merger Consideration over the per-share exercise price of such option, less any applicable tax withholding

Footnote F5

These options became exercisable on February 26, 2023.

Footnote F6

These options became exercisable on February 14, 2024.